New drugs: nebivolol hydrochloride, nilotinib, and sapropterin dihydrochloride.
Hussar
Daniel A
DA
Pharmacy Philadelphia College of Pharmacy University of Science in Philadelphia Philadelphia, Pa.
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001578:Benzopyrans / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001708:Biopterins / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004983:Ethanolamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D000068577:Nebivolol; D010661:Phenylketonurias / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D001578:Benzopyrans; D004983:Ethanolamines; D011743:Pyrimidines; D000068577:Nebivolol; D001708:Biopterins; C003402:sapropterin; C498826:nilotinib